Ensayos clínicos

8.676 ensayos encontrados

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia y seguridad del agente reductor de amiloide ALXN2220 en participantes adultos con miocardiopatía por amiloide de transtiretina (ATTR-CM)

IntervencionalInicio: 11 de ene de 2024ID: NCT06183931

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio de fase 3, aleatorizado, doble ciego, de MK-7684A en combinación con etopósido y platino seguido de MK-7684A versus atezolizumab en combinación con etopósido y platino seguido de atezolizumab para el tratamiento de primera línea de participantes con cáncer de pulmón de células pequeñas en estadio extenso (KEYVIBE-008)

IntervencionalInicio: 24 de mar de 2022ID: NCT05224141

ReclutandoFase 3ClinicalTrials.gov

Estudio de fase III para evaluar la eficacia y seguridad de NEXIUM en el mantenimiento de la curación de la esofagitis erosiva en pacientes pediátricos de 1 a 11 años de edad

IntervencionalInicio: 1 de jul de 2022ID: NCT05267613

ReclutandoFase 2ClinicalTrials.gov

Ensayo Clínico de Fase III, Aleatorizado, Doble Ciego, Controlado con Placebo, de Grupos Paralelos y Multicéntrico para Evaluar la Eficacia y Seguridad de 2 Dosis de Buloxibutid durante 52 Semanas en Personas con Fibrosis Pulmonar Idiopática.

IntervencionalInicio: 9 de dic de 2024ID: NCT06588686

CompletadoClinicalTrials.gov

Prevalencia de mutaciones en genes de reparación por recombinación homóloga (HRR) en pacientes con cáncer de próstata metastásico resistente a la castración en América Latina: estudio PROSPECT.

ObservacionalInicio: 21 de abr de 2021ID: NCT04962880

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar el efecto de tirzepatida sobre la reducción de la morbilidad y la mortalidad en adultos con obesidad

IntervencionalInicio: 11 de oct de 2022ID: NCT05556512

CompletadoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)

IntervencionalInicio: 25 de mar de 2019ID: NCT03829319

CompletadoFase 3ClinicalTrials.gov

A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment

IntervencionalInicio: 1 de feb de 2011ID: NCT01250379

CompletadoFase 3ClinicalTrials.gov

A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures

IntervencionalInicio: 1 de may de 2006ID: NCT00355082

CompletadoFase 3ClinicalTrials.gov

A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

IntervencionalInicio: 20 de nov de 2014ID: NCT02278120

CompletadoFase 3ClinicalTrials.gov

Multicentric Evaluator-blinded Randomized Non-inferiority Study, to Asses the Compared Efficacy, Safety and Immunogenicity of Enerceptan® With Enbrel® in Combination With Methotrexate for the Treatment of Patients With Rheumatoid Arthritis

IntervencionalInicio: 1 de feb de 2016ID: NCT03332719

CompletadoFase 3ClinicalTrials.gov

STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE

IntervencionalInicio: 15 de abr de 2016ID: NCT02600923

CompletadoClinicalTrials.gov

Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection

ObservacionalInicio: 1 de ene de 2010ID: NCT01869010

DesconocidoClinicalTrials.gov

Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome

ObservacionalInicio: 1 de dic de 2007ID: NCT00784615

CompletadoClinicalTrials.gov

An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses

ObservacionalInicio: 1 de ago de 2009ID: NCT01056354

CompletadoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)

IntervencionalInicio: 20 de ene de 2015ID: NCT02314117

TerminadoFase 3ClinicalTrials.gov

Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.

IntervencionalInicio: 1 de jul de 2006ID: NCT00359437

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis

IntervencionalInicio: 23 de feb de 2016ID: NCT02706873

CompletadoFase 3ClinicalTrials.gov

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

IntervencionalInicio: 11 de oct de 2017ID: NCT03199053

CompletadoFase 2ClinicalTrials.gov

Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria

IntervencionalInicio: 1 de feb de 2006ID: NCT00296374